PAVmed Inc. (NASDAQ:PAVM) Short Interest Update

PAVmed Inc. (NASDAQ:PAVM) was the recipient of a large decline in short interest in the month of December. As of December 15th, there was short interest totaling 427,310 shares, a decline of 27.0% from the November 30th total of 585,084 shares. Based on an average daily volume of 322,686 shares, the short-interest ratio is presently 1.3 days. Currently, 1.6% of the company’s shares are short sold. Currently, 1.6% of the company’s shares are short sold. Based on an average daily volume of 322,686 shares, the short-interest ratio is presently 1.3 days.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on PAVM shares. Weiss Ratings reissued a “sell (d)” rating on shares of PAVmed in a research note on Wednesday, October 8th. Ascendiant Capital Markets reduced their target price on PAVmed from $20.00 to $17.00 and set a “buy” rating on the stock in a research note on Wednesday, December 10th. Finally, Zacks Research downgraded PAVmed from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 24th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $17.00.

PAVmed Price Performance

NASDAQ PAVM traded down $0.05 during midday trading on Tuesday, hitting $0.24. 2,521,303 shares of the company traded hands, compared to its average volume of 286,425. PAVmed has a 52 week low of $0.21 and a 52 week high of $0.90. The company’s 50-day simple moving average is $0.35 and its 200-day simple moving average is $0.45. The company has a market cap of $7.00 million, a PE ratio of -0.41 and a beta of 1.09.

PAVmed shares are going to reverse split on Friday, January 2nd. The 1-30 reverse split was announced on Tuesday, December 30th. The number of shares owned by shareholders will be adjusted after the closing bell on Wednesday, December 31st.

Hedge Funds Weigh In On PAVmed

An institutional investor recently raised its position in PAVmed stock. Jane Street Group LLC boosted its stake in shares of PAVmed Inc. (NASDAQ:PAVM) by 392.9% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 52,676 shares of the company’s stock after acquiring an additional 41,990 shares during the period. Jane Street Group LLC owned about 0.31% of PAVmed worth $32,000 at the end of the most recent quarter. Institutional investors and hedge funds own 19.93% of the company’s stock.

About PAVmed

PAVmed Inc is a clinical-stage medical technology company focused on acquiring, developing and commercializing innovative medical devices aimed primarily at gastrointestinal endoscopy and related therapeutic areas. Its portfolio includes FDA-cleared products such as EsoFLIP® Distensibility System for the treatment of esophageal strictures and MUSE™ (Medigus Ultrasonic Surgical Endostapler) for endoscopic fundoplication in gastroesophageal reflux disease (GERD). In addition to its gastrointestinal franchise, PAVmed is advancing early-stage programs targeting indications in oncology, urology and dermatology.

Founded in 2012, PAVmed has built its pipeline through internal research and development as well as strategic collaborations and acquisitions.